Ambrisentan and Tadalafil combination highly effective in scleroderma associated PAH

By Dr Deepu

Scleroderma associated PAH is a rare entity and has a very dismal response to currently available Pulmonary arterial hypertension therapy. Hasson et al recently published a study in AJRCCM November issue (vol 192 no.9). They assessed the effect of up-front combination PAH therapy in ssc-PAH.
 Patients, newly diagnosed with SSc- PAH  were given ambrisentan 10mg and Tadalafil daily for 36 weeks.
Primary endpoints - Right ventricular mass and Pulmonary Vascular resistance (Functional, hemodynamic and Imaging )
Secondary end points- stroke volume, 6MWD, pro-bnp .
Results showed a reduction in median RV mass and mean pulmonary vascular resistance and a improved median Stoke volume, 6MWD, pro-bnp.
So the study demonstrated, up-front combination therapy with ambrisentan and Tadalafil could be very effective in treatment naive SSc- PAH.
Read the research paper

No comments:

Post a Comment

Please leave your comments